Modulation of the typical multidrug resistance phenotype by targeting the MED-1 region of human MDR1 promoter

Gene Therapy

Volumn 7, Issue 14, 2000, Pages 1224-1233

  Marthinet, E ^a   Divita, G ^b   Bernaud, J ^c   Rigal, D ^c   Baggetto, L G ^a  

^a INSTITUT DE BIOLOGIE ET CHIMIE DES PROTÉINES   (France)

^b Centre National de la Recherche Scientifique   (France)

^c ETS   (France)

Author keywords

MDR1 gene; MED 1; Multidrug resistance; P glycoprotein; Peptide vector; Transcriptional decoy

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CIS ACTING ELEMENT; GLYCOPROTEIN P; GREEN FLUORESCENT PROTEIN; MEMBRANE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; VINBLASTINE;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CELL VIABILITY; CONTROLLED STUDY; FLUORESCENCE; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TATA BOX; TREATMENT FAILURE;

ANIMALIA;

EID: 0033914906     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301231     Document Type: Article

References (47)

1. Biochemical, genetic, and metabolic adaptations of tumor cells that express the typical multidrug-resistance phenotype. Reversion by new therapies
2. The mdr1 gene, responsible for multidrug-resistance, codes for P- glycoprotein
3. Secondary structure of P-glycoprotein investigated by circular dichroism and amino acid sequence analysis
4. Isolation and expression of a complementary DNA that confers multidrug resistance
5. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
6. Non-P-glycoprotein novel proteins involved in human cancer multidrug- resistance
7. Distantly related sequences in the α- and β-subunits of ATPsynthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold
8. Binding protein-dependent transport systems
9. Isolation and sequence of the promoter region of the human multidrug resistance (P-glycoprotein) gene
10. Identification of a functional initiator sequence in the human MDR1 promoter
11. The 'initiator' as a transcription control element
12. A conserved downstream element defines a new class of RNA polymerase II promoters
13. Differential utilization of multiple transcription start points accompanies the overexpression of the P-glycoprotein-encoding gene in Chinese hamster lung cells
14. Stable transfection of the P-glycoprotein promoter reproduces the endogenous over expression phenotype: The role of MED-1
15. Pharmacologic circumvention of multidrug resistance
16. In vitro and in vivo reversal of cancer cell multidrug resistance by the semi-synthetic antibiotic tiamulin
17. Identification of the multiple resistance-related P-glycoprotein as a cyclosporine binding protein
18. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZPSC 833, a non-immunosuppressive cyclosporin derivative
19. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance
20. Specific regulation of gene expression by antisense, sense and antigene nucleic acids
21. Progress in antisense oligonucleotide therapeutics
22. Modulation of multidrug resistance by verapamil or mdr1 anti-sense oligodeoxynucleotide does not change the high susceptibility to lymphokine-activated killers in MDR-resistant human carcinoma (LoVo) line
23. Effect of unmodified triple helix-forming oligodeoxyribonucleotide targeted to human multidrug-resistance gene mdr1 in MDR cancer cells
24. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides
25. Novel chemically modified oligonucleotides provide potent inhibition of P-glycoprotein expression
26. Inhibition of P-glycoprotein and recovery of drug sensitivity of human acute leukemic blast cells by multidrug resistance gene (mdr1) antisense oligonucleotides
27. Modulation of P-glycoprotein-mediated multidrug resistance in a doxorubicin-resistant subline of the human lymphoblastoid cell line CCRFCEM by phosphorothioate antisense oligonucleotides
28. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells
29. Application of transcription factor 'decoy' strategy as means of gene therapy and study of gene expression in cardiovascular disease
30. Potent inhibition of human immunodeficiency virus type 1 (HIV-1) gene expression and virus production by an HIV-2 tat activation-response RNA decoy
31. Gene regulation by decoy approach (I): Synthesis and properties of photocrosslinked oligonucleotides
32. Transcriptional regulation of the human proenkephalin gene by conformational switching: Implications for decoy design
33. Identification of cis-elements of the human endothelin-A receptor gene and inhibition of the gene expression by the decoy strategy
34. Modulation of estrogen receptor gene expression in human breast cancer cells: A decoy strategy with specific PCR-generated DNA fragments
35. Dual blockade of cyclic AMP response element- (CRE) and AP-1-directed transcription by CRE-transcription factor decoy oligonucleotide. Gene- specific inhibition of tumor growth
36. Efficient purification and reconstitution of P-glycoprotein for functional and structural studies
37. Cellular uptake and intracellular fate of antisense oligonucleotides
38. A novel potent strategy for gene delivery using a single peptide vector as a carrier
39. Modulation of P-glycoprotein-mediated multidrug resistance by monoclonal antibodies, immunotoxins or antisense oligodeoxynucleotides in kidney carcinoma and normal kidney cells
40. Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotides
41. Improvement of hammerhead ribozymes cleaving mdr-1 mRNA
42. Selective reversal of drug resistance in drug-resistant lung adenocarcinoma cells by tumor-specific expression of MDR1 ribozyme gene mediated by retrovirus
43. Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras
44. Intracellular localization of oligonucleotides: Influence of fixative protocols
45. Inactivation of MED-1 elements in the TATA-less, initiator-less mouse thymidylate synthase promoter has no effect on promoter strength or the complex pattern of transcriptional start sites
46. Cell culture for biochemists
47. Non-radioisotopic AFLP method using PCR primers fluorescently labeled with Cy5